Literature DB >> 19525183

Multiple significant bortezomib-related toxicities in one patient: case report and literature review.

Jeanette M Waller1, John C Moretto, Kevin B Knopf.   

Abstract

Bortezomib has shown significant efficacy in the treatment of patients with relapsed multiple myeloma (MM) and is generally well tolerated. We report a 65-year-old male patient undergoing bortezomib therapy for MM who, with the addition of liposomal doxorubicin, presented with severe paralytic ileus, peripheral neuropathy, pruritic rash, and testicular pain. Each of these toxicities was temporally related to the bortezomib-based therapy and the administration of concomitant liposomal doxorubicin. Herein, we discuss the patient's course and briefly review the literature on these bortezomib combination-related toxicities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525183     DOI: 10.3816/CLM.2009.n.051

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  3 in total

1.  A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.

Authors:  T-F Wang; M A Fiala; A F Cashen; G L Uy; C N Abboud; T Fletcher; N Wu; P Westervelt; J F DiPersio; K E Stockerl-Goldstein; R Vij
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

2.  Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function.

Authors:  Matthew Keating; Constantin A Dasanu
Journal:  BMJ Case Rep       Date:  2016-11-29

3.  A rare case report of multiple myeloma presenting with paralytic ileus and type II respiratory failure due to hypercalcemic crisis.

Authors:  Yuchen Guo; Liang He; Yiming Liu; Xueyuan Cao
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.